BioSpace News Archive

Press Releases

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

October 27, 2025
·
5 min read
Press Releases

23andMe Research Institute Names Brad Margus and Stephen Quake, D.Phil., to Board of Directors

October 27, 2025
·
3 min read
Press Releases

ProPhase Labs to Present at the 2025 ThinkEquity Conference

October 27, 2025
·
1 min read
Press Releases

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

October 27, 2025
·
10 min read
Press Releases

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

October 27, 2025
·
8 min read
Press Releases

Halda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC™ Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

October 27, 2025
·
6 min read
Press Releases

Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 27, 2025
·
4 min read
Press Releases

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

October 27, 2025
·
7 min read
Press Releases

Lilly to Acquire Adverum Biotechnologies

October 27, 2025
·
13 min read
Press Releases

TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor with a fully subcutaneous dose regimen

October 27, 2025
·
19 min read